Aims Objective of this study was to investigate whether adenosine modulates renal erythropoietin production. Methods In the present study erythropoietin production was stimulated by hypobaric hypoxia by subjecting healthy volunteers to a simulated altitude of 4000 m in a low pressure chamber for 5.5 h. During exposure to hypoxia the subjects received i.v. in a randomized, single-blind, cross-over fashion the non-specific adenosine antagonist theophylline, the adenosine reuptake inhibitor dipyridamole and placebo. Results Contrary to the working hypothesis, theophylline did not decrease and dipyridamole did not further boost erythropoietin concentrations. Conclusions The results are in agreement with our earlier study using haemorrhage as a controlled physiological stimulus of erythropoietin production, and would question a major role for adenosine as a mediator of renal erythropoietin production.
Introduction some animal experiments [2] . Therefore, in a similar experimental design using theophylline and dipyridamole There is some evidence from in vitro and animal experiments for the assumption that adenosine (ADO) might modulate treatment, EPO production was stimulated by hypobaric hypoxia by subjecting healthy volunteers to a simulated renal erythropoietin (EPO) production [1] . According to this hypothesis, increasing renal ADO levels (e.g. under altitude of 4000 m in a low pressure chamber. hypoxia [2] ) would lead to an increased production of EPO and vice versa. Also, clinical data are available which may Methods point towards such a role for ADO in humans. Bakris et al. [3] have shown that theophylline treatment in patients with Subjects post-transplant erythrocytosis (PTE) may reduce elevated Seven healthy male non-smoking volunteers (mean age 25.1 EPO levels as well as haematocrit. However, this finding years, range 20-31 years, mean body weight 75.3 kg, range has not been unequivocally reproduced [4] and PTE is not 68-86 kg) participated in the trial. The conditions for considered a condition where the pharmacological control participation were identical with the earlier study [7] . The of EPO production can appropriately be assessed [5] . study was approved by the Ethics Committee of the Our own animal experiments which assessed the ADO University of Göttingen and the Ethics Committee of hypothesis systematically using selective adenosinergic comthe Board of Physicians Nordrhein, Dü sseldorf, Germany. pounds (not available for human use) in a model of Written, informed consent was obtained from each functional hypoxia (by CO exposure) were unable to participant. support this hypothesis [6] . Also, in a previous study we tried to assess this question in healthy volunteers who were subjected to a defined physiological stimulus of EPO Protocol production, namely haemorrhage. In this experiment the The volunteers were subjected to hypoxia in a hypobaric non-specific ADO antagonist theophylline did not inhibit chamber according to the protocol of Eckardt et al. [8] . In the increase of EPO levels as predicted from the hypothesis brief, the atmospheric pressure was reduced to 460 Torr [7] . The ADO reuptake inhibitor dipyridamole increases (4000 m above sea level) with an interruption for 15 min at extracellular ADO levels. From theory and animal experi-600 Torr during the ascent (2000 m above sea level). The ments it is expected to augment renal ADO effects [8] . In subjects remained in the chamber for a total of 5.5 h. Thirty our previous experiment dipyridamole did not boost EPO min before the subjects were exposed to hypoxia i.v. drug levels [7] despite dipyridamole plasma levels which had been medication was started and administered for 6 h by an shown to inhibit ADO uptake in human platelets [9] . infusion pump (PerfusorA, Braun Melsungen AG, Germany) However, haemorrhage may not exert a signal to EPO until the end of the stay in the chamber. The subjects received in a randomized, cross-over, single-blind design blood pressure fell during the first 2 h of hypoxia (P >0.05), mean diastolic blood pressure was about 5 mmHg lower during infusion of theophylline during the first 2 h of hypoxia (P<0.05). Otherwise there were no major changes of blood pressure during the entire experiment (data not shown h −1 )·h)). Baseline EPO levels were 3.5±0.5 (theophylline), 5.4±0.6 (dipyridamole) and 4.4±0.6 mu ml −1 ( placebo).
The time course of EPO concentrations is given in Figure 1 . There were no statistically significant differences between 
Discussion
The results concerning the course of blood pressure and loading dose over 20 min, followed by a continuous infusion of 0.5 mg kg −1 h −1 over the remaining 340 min; Euphyllin heart rate from the placebo group were in accordance with earlier observations using the same hypobaric protocol [10]; 200A), or dipyridamole (0.21 mg kg
The treatments were separated by wash out periods of at the verum treatments did not alter the obviously hypoxiarelated changes. Theophylline and dipyridamole concenleast 2 weeks. In the chamber the subjects remained in the sitting position. Arterial haemoglobin oxygen saturation trations were comparable with those achieved in our first study [7] . Thus, theophylline plasma concentrations were in (SaO 2 ) was measured by a pulse oximeter with a fingerclip sensor. Haemoglobin and haematocrit were measured before the range for the treatment of asthma and effective blockade of ADO receptors is assumed [11] . Plasma concentrations of hypoxia and 2, 6, 24, and 48 h thereafter. Blood pressure and heart rate were recorded before, and 2, 4, 6, 8 and 12 h this order of magnitude have been achieved in patients with effective control of PTE [3] . Dipyridamole plasma concenafter the start of hypoxia. Drug concentrations were measured before and after 4 h of the respective drug trations were of the order of magnitude where an inhibition of ADO reuptake was demonstrated in platelets of normal infusions. Blood samples for EPO concentrations were taken as shown in Figure 1 . Plasma renin activity (PRA) was subjects after oral administration [9] . The increase of EPO during placebo treatment was similar measured before hypoxia as well as 2, 4, 6, 8, and 12 h thereafter.
to that in the study by Eckardt et al. [8] . The onset of EPO production was more rapid than after phlebotomy [7] . However, in agreement with this earlier study, there was no Analytical methods and statistics inhibition of EPO production by theophylline and no further boost by dipyridamole. In fact, we found-as in our Haemoglobin, haematocrit, dipyridamole and theophylline, PRA and EPO were analysed as described previously [7] .
earlier study-an increase of EPO production under theophylline; this increase was not statistically significant. The area under the concentration-time curve (AUC) was calculated by the linear trapezoidal rule. Values are expressed Also, PRA values were of the same order of magnitude as in our previous study [7] , confirming that hypoxia did not as mean±s.e.mean and were analyzed by repeated measures ANOVA followed in the case of a significant finding by change the effect of the treatments on PRA. A clear increase during theophylline infusion was demonstrated. PRA is a t-tests with Bonferroni-Holm correction.
variable that is modulated by sympathoadrenergic signals [12] . As outlined earlier, theophylline may block presynaptic Results adenosine receptors thereby increasing sympathetic signal transduction. This led us to conclude that the further Oxygen saturation fell in all groups from 100% to about 85% during hypoxia. Within the 48 h observation period increase of EPO levels under theophylline may be caused by an increased sympathetic tone. Another trial has addressed after the start of hypoxia, haemoglobin and haematocrit values were very similar in all groups and unaltered by this hypothesis, and a clear stimulating effect was shown for the b 2 -adrenoceptor agonist fenoterol [13] .Taken together, treatment (data not shown). Four hours after the start of the i.v. drug infusion the mean plasma concentration of these data are in agreement with those from our experiment using phlebotomy and do not support a role for adenosine theophylline was 13.7±0.4 mg l −1 and that of dipyridamole 1.5±0.2 mg ml . In all treatment groups mean systolic in the control of erythropoietin production.
